BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 18619971)

  • 1. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study.
    Malfertheiner P; Schultze V; Rosenkranz B; Kaufmann SH; Ulrichs T; Novicki D; Norelli F; Contorni M; Peppoloni S; Berti D; Tornese D; Ganju J; Palla E; Rappuoli R; Scharschmidt BF; Del Giudice G
    Gastroenterology; 2008 Sep; 135(3):787-95. PubMed ID: 18619971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy.
    Rossi G; Ruggiero P; Peppoloni S; Pancotto L; Fortuna D; Lauretti L; Volpini G; Mancianti S; Corazza M; Taccini E; Di Pisa F; Rappuoli R; Del Giudice G
    Infect Immun; 2004 Jun; 72(6):3252-9. PubMed ID: 15155627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.
    Malfertheiner P; Selgrad M; Wex T; Romi B; Borgogni E; Spensieri F; Zedda L; Ruggiero P; Pancotto L; Censini S; Palla E; Kanesa-Thasan N; Scharschmidt B; Rappuoli R; Graham DY; Schiavetti F; Del Giudice G
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):698-707. PubMed ID: 30042064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers.
    Metzger WG; Mansouri E; Kronawitter M; Diescher S; Soerensen M; Hurwitz R; Bumann D; Aebischer T; Von Specht BU; Meyer TF
    Vaccine; 2004 Jun; 22(17-18):2273-7. PubMed ID: 15149786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The C-terminally encoded, MHC class II-restricted T cell antigenicity of the Helicobacter pylori virulence factor CagA promotes gastric preneoplasia.
    Arnold IC; Hitzler I; Engler D; Oertli M; Agger EM; Müller A
    J Immunol; 2011 Jun; 186(11):6165-72. PubMed ID: 21518972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.
    Hatzifoti C; Roussel Y; Harris AG; Wren BW; Morrow JW; Bajaj-Elliott M
    Helicobacter; 2006 Apr; 11(2):113-22. PubMed ID: 16579841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection.
    Shi T; Liu WZ; Gao F; Shi GY; Xiao SD
    Helicobacter; 2005 Feb; 10(1):71-9. PubMed ID: 15691317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and evaluation of a DNA vaccine based on Helicobacter pylori urease B: failure to prevent experimental infection in the mouse model.
    Zavala-Spinetti L; Breslin MB; Correa H; Bégué RE
    Helicobacter; 2006 Dec; 11(6):517-22. PubMed ID: 17083372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroreactivity to specific antigens of Helicobacter pylori infection is associated with an increased risk of the dyspeptic gastrointestinal diseases.
    Chomvarin C; Ottiwet O; Hahnvajanawong C; Intapan PM; Wongwajana S
    Int J Infect Dis; 2009 Sep; 13(5):647-54. PubMed ID: 19233700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against Helicobacter pylori infection in mongolian gerbil by intragastric or intramuscular administration of H. pylori multicomponent vaccine.
    Wu C; Shi Y; Guo H; Zou WY; Guo G; Xie QH; Mao XH; Tong WD; Zou QM
    Helicobacter; 2008 Jun; 13(3):191-9. PubMed ID: 18466394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
    Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
    Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of subcutaneous or intramuscular administration of a monovalent inactivated vaccine against Leptospira interrogans serogroup Icterohaemorrhagiae in healthy volunteers.
    Laurichesse H; Gourdon F; Smits HL; Abdoe TH; Estavoyer JM; Rebika H; Pouliquen P; Catalina P; Dubray C; Beytout J
    Clin Microbiol Infect; 2007 Apr; 13(4):395-403. PubMed ID: 17359323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization.
    Gottwein JM; Blanchard TG; Targoni OS; Eisenberg JC; Zagorski BM; Redline RW; Nedrud JG; Tary-Lehmann M; Lehmann PV; Czinn SJ
    J Infect Dis; 2001 Aug; 184(3):308-14. PubMed ID: 11443556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design of vaccines against Helicobacter pylori and their development.
    Del Giudice G; Covacci A; Telford JL; Montecucco C; Rappuoli R
    Annu Rev Immunol; 2001; 19():523-63. PubMed ID: 11244046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status of Helicobacter pylori vaccines: a review.
    Kabir S
    Helicobacter; 2007 Apr; 12(2):89-102. PubMed ID: 17309745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of vaccines against Helicobacter pylori.
    Del Giudice G; Malfertheiner P; Rappuoli R
    Expert Rev Vaccines; 2009 Aug; 8(8):1037-49. PubMed ID: 19627186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a new tumor necrosis factor-alpha-inducing membrane protein of Helicobacter pylori as a prophylactic vaccine antigen.
    Inoue K; Shiota S; Yamada K; Gotoh K; Suganuma M; Fujioka T; Ahmed K; Iha H; Nishizono A
    Helicobacter; 2009 Oct; 14(5):135-43. PubMed ID: 19751439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection.
    Kotloff KL; Sztein MB; Wasserman SS; Losonsky GA; DiLorenzo SC; Walker RI
    Infect Immun; 2001 Jun; 69(6):3581-90. PubMed ID: 11349017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of oral immunization with attenuated Salmonella typhimurium expressing Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model.
    Liu KY; Shi Y; Luo P; Yu S; Chen L; Zhao Z; Mao XH; Guo G; Wu C; Zou QM
    Vaccine; 2011 Sep; 29(38):6679-85. PubMed ID: 21745524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of B cell responses in the stomach of Helicobacter pylori- infected subjects after oral cholera vaccination.
    Mattsson A; Lönroth H; Quiding-Järbrink M; Svennerholm AM
    J Clin Invest; 1998 Jul; 102(1):51-6. PubMed ID: 9649556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.